Heroin |
|
|
Clinical Trial: Effects of Dynorphin 1-13 on Heroin Addiction - 1
This study has been completed.
Purpose
The purpose of this study is to evaluate the effects of IV dynorphin in humans during acute heroin abstinence, in order to determine that dynorphin suppresses acute opiate withdrawal, reduces opiate craving, and is safe at doses required to produce the above effects.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Opioid-Related Disorders Substance Withdrawal Syndrome | Drug: Dynorphin 1 - 13 | Phase II |
MedlinePlus related topics: Drug Abuse; Prescription Drug Abuse
Study Type: Interventional
Study Design: Treatment, Double-Blind, Placebo Control
Official Title: Effects of Dynorphin 1-13 on Heroin Addiction
Study start: August 1994; Study completion: August 1995
Randomized double blinded study of the effects of a single IV dose of dynorphin A 1-13 on heroin withdrawal in human opiate addicts
Eligibility
Ages Eligible for Study: 18 Years - 55 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
opiate addict between the ages of 18-55
Exclusion Criteria:
Regular abuse of other drugs, unstable medical conditions
Location Information
Minnesota
U of Minnesota School of Medicine, Minneapolis, Minnesota, 55415, United States
Paul Pentel, M.D., Principal Investigator, University of Minnesota
More Information
Publications
Specker S, Wananukul W, Hatsukami D, Nolin K, Hooke L, Kreek MJ, Pentel PR. Effects of dynorphin A(1-13) on opiate withdrawal in humans. Psychopharmacology (Berl). 1998 Jun;137(4):326-32.
Record last reviewed: August 1995
Last Updated: November 18, 2004
Record first received: September 20, 1999
ClinicalTrials.gov Identifier: NCT00000244
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Heroin (Cleveland Clinic)
- Heroin: Abuse and Addiction (Cleveland Clinic)

Not Signed In -

